Final_ppt of Shoma
-
Upload
sadia-sharmin-nilima -
Category
Documents
-
view
108 -
download
0
Transcript of Final_ppt of Shoma
![Page 1: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/1.jpg)
Comparative analysis of HCV RNA, Anti-HCV and liver Transaminase levels:
predominance of HCV genotype
Fahmida NasrinID No: 1030883070MS in BiotechnologyDept. of Biochemistry & MicrobiologyNorth South University
![Page 2: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/2.jpg)
Background
Hepatitis C Virus
![Page 3: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/3.jpg)
At least 50% of patients develop chronic liver disease. Cirrhosis develops in about 20-30% within 5-30years. 15% develops hepatocellular carcinoma. Assess baseline viral load prior to initiation therapy Determine therapeutic success during and after therapy. Assessment of prognosis and disease progression.
Rationale of the study
![Page 4: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/4.jpg)
Replication of HCV
![Page 5: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/5.jpg)
Route of transmission Percentage
Injection Drug use 60%
Sexual 15%
Transfussion 10%
Occupation 4%
Other 1%
Unknown 10% 0%
10%
20%
30%
40%
50%
60%
70%
60%
15%10%
4% 1%
10%
Percentage
Transmission
![Page 6: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/6.jpg)
Serologic Pattern of Acute HCV Infection with Recovery
![Page 7: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/7.jpg)
Serologic Pattern of Acute HCV Infection with Progression to Chronic Infection
![Page 8: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/8.jpg)
Epidemiology of Hepatitis C
![Page 9: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/9.jpg)
Aims of the study This study was carried out : 1. to correlate serological marker of HCV and liver function
tests as an alternative to HCV RNA estimation. 2. to evaluate the state of infection among Anti-HCV positive
patients. 3. to decide the indication of therapy 4. to find out discordance of seromarkers with HCV RNA.
![Page 10: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/10.jpg)
Materials and Method
Place of the study The study was conducted in- DNA Solution Ltd. Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka.
Study period This study was done during the period of April 2011 to November 2011.
Study design Cross sectional study.
![Page 11: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/11.jpg)
Subjects
-Inclusion criteria Subjects with age ranging from 15-80 years. 120 patients diagnosed as a case.
-Exclusion criteria Patients with serious co-morbid disease (severe infection, stroke, myocardial onfarction, major surgery, mal-absorption etc).
![Page 12: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/12.jpg)
Laboratory Analyses
Anti-HCV: Enzyme Linked Immunosorbent Assay (ELISA), Fortress Diagnostic-USA.
Serum ALT, AST: enzymatic assay, Randox-Germany. HCV RNA: Real-time Reverse Transcription PCR,
Roboscreen-Germany. HCV genotyping: Real-time Reverse Transcription PCR,
Sacace-Italy.Statistical Analysis All data were analyzed by using Statistical Package for
Social Science (SPSS) for Windows version 12.0. p value <0.05 was taken as level of significance.
![Page 13: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/13.jpg)
Results
![Page 14: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/14.jpg)
Age & sex distribution of subjects
Male Female0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
% of subjects
Sex No. of subjects (%)
Male86 (71.66)
Female34 (28.33)
Age (years) No. of subjects (%)<20 8 (6.66)
21-40 68 (56.66)41-60 42 (35)61-75 2 (1.66)
<20 21-40 41-60 61-750.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
% of subjects
Age (years)
![Page 15: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/15.jpg)
Prevalence of HCV infection in different age groups in male
0-10 11 to 20 21 to 30 31 to 40 41 to 60 61 to 7505
10152025303540
No. of male subjects
Age group No. of male subjects0-10 0
11-20 621-30 3531-40 1741-60 2661-75 2
![Page 16: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/16.jpg)
Prevalence of HCV infection in different age groups in female
Age group No. of female subjects0-10 0
11-20 221-30 1831-40 1041-60 361-75 1
0-10 11 to 20 21 to 30 31 to 40 41 to 60 61 to 7502468
101214161820
No. of female subjects
![Page 17: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/17.jpg)
0-10 11 to 20 21 to 30 31 to 40 41 to 60 61 to 7505
10152025303540
No. of male subjectsNo. of female subjects
Age group No. of male subjects
No. of female subjects
0 -10 0 011-20 6 221-30 35 1831- 40 17 1041- 60 26 361-75 2 1
Prevalence of HCV infection in different age groups in male & female
![Page 18: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/18.jpg)
Correlation between Anti-HCV & HCV RNA
p=0.692
Positive HCV RNA Negative HCV RNA0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
68.91
31.09
100.00
0.00
Positive Anti-HCV Negative Anti-HCV
Positive Anti-HCV n=119
(%)
Negative Anti-HCV, n=01 (%)
Positive HCV RNA 82 (68.91) 1 (100.0)
Negative HCV RNA 37 (31.09) 0 (0.0)
![Page 19: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/19.jpg)
Correlation between Anti-HCV and ALT
p=0.492
Raised ALT Normal ALT0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
48.74 51.26
100.00
0.00
Positive Anti-HCV Negative Anti-HCV
Positive
Anti-HCV, n=119 (%)
Negative Anti-HCV, n=01 (%)
Raised ALT 58 (48.47) 1 (100.0)
Normal ALT 61 (51.26) 0 (0.0)
![Page 20: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/20.jpg)
Correlation between Anti-HCV and AST
p=0.433
Raised AST Normal AST0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
42.86
57.14
100.00
0.00
Positive Anti-HCV Negative Anti-HCV
Positive
Anti-HCV, n=119 (%)
Negative Anti-HCV, n=01 (%)
Raised AST 51 (42.86) 1 (100.0)
Normal AST 68 (57.14) 0 (0.0)
![Page 21: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/21.jpg)
Correlation between HCV RNA and ALT
p=0.549
Raised ALT Normal ALT40.00
42.00
44.00
46.00
48.00
50.00
52.00
54.00
56.00
49.40
50.60
45.95
54.05
Positive HCV RNA Negative HCV RNA
Positive
HCV RNA, n=83 (%)
Negative HCV RNA, n=37 (%)
Raised ALT 41 (49.40) 17 (45.95)
Normal ALT 42 (50.60) 20 (54.05)
![Page 22: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/22.jpg)
Correlation between HCV RNA and AST
p=0.425
Raised AST Normal AST0.00
10.00
20.00
30.00
40.00
50.00
60.00
42.17
57.83
45.96
54.05
Positive HCV RNA Negative HCV RNA
Positive
HCV RNA, n=83 (%)
Negative HCV RNA, n=37 (%)
Raised AST 35 (42.17) 17 (45.96)
Normal AST 48 (57.83) 20 (54.05)
![Page 23: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/23.jpg)
Frequencies of liver transaminases with HCV RNA & Anti-HCV
HCV RNA
Positive (n=83) Negative (n=37)
ALT+AST ALT AST ALT+AST ALT AST
Raised 33 (39.76%) 8 (9.64%) 2
(2.41%)15
(40.54%)3
(8.11%) 2 (5.41%)
Normal 40 (48.19%) 17 (45.95%)
Anti-HCV
Positive (n=119) Negative (n=01)
ALT+AST ALT AST ALT+AST ALT AST
Raised 47 (39.50%) 11(9.24%) 4 (3.36%) 1 (100.0%) 0 (0.0%) 0 (0.0%)
Normal 57 (47.90%) 0 (0.0%)
![Page 24: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/24.jpg)
Viral Load 0 1-10^3 10^4 10^5 10^6 10^7 10^8
Raised ALT 19 (51.35) 5 (62.50) 7 (70.00) 10 (47.62) 9 (52.94) 7 (48.18) 4 (40.00)
Normal ALT 18 (48.65) 3 (37.50) 3 (30.00) 11 (52.38) 8 (47.06) 10 (58.82) 6 (60.00)
Correlation between Viral load and ALT
0 1-10^3 10^4 10^5 10^6 10^7 10^80.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
51.35
62.5070.00
47.6252.94
41.18 40.00
48.65
37.5030.00
52.3847.06
58.82 60.00
Raised ALT Normal ALT
p=0.792
![Page 25: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/25.jpg)
Correlation between Viral load and AST
Viral Load 0 1-10^3 10^4 10^5 10^6 10^7 10^8
Raised AST 20 (54.05) 5 (62.50) 8 (80.00) 11 (52.38) 10 (58.82) 10 (58.82) 4 (40.00)
Normal AST 17 (45.95) 3 (37.50) 2 (20.00) 10 (47.62) 7 (41.18) 7 (41.18) 6 (60.00)
0 1-10^3 10^4 10^5 10^6 10^7 10^80.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
54.0562.50
80.00
52.3858.82 58.82
40.0045.95
37.50
20.00
47.6241.18 41.18
60.00
Raised AST Normal AST
p=0.706
![Page 26: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/26.jpg)
Prevalence of HCV genotype Genotype No. of subjects (%)
1a 4 (3.33)1b 3 (2.5)2 1 (0.83)3 103 (85.83)4 1 (0.83)
5 or 6 8 (0.67)
1a 1b 2 3 4 5 or 6 0
10
20
30
40
50
60
70
80
90
3.33 2.50.83000000000
0001
85.83
0.830000000000001
6.67
No. of subjects (%)
![Page 27: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/27.jpg)
Summary
1.There is no significant correlation between Anti-HCV to HCV RNA (P=0.692).
![Page 28: Final_ppt of Shoma](https://reader034.fdocuments.us/reader034/viewer/2022051815/53fd57c5dab5ca8b6d8b4635/html5/thumbnails/28.jpg)
As a result since Anti-HCV negativity may be detected in viremic patients molecular methods should be applied specially for suspected cases.
Conclusion